Witnessing the stock’s movement on the chart, on Wednesday, BioNTech SE ADR (NASDAQ: BNTX) set off with pace as it heaved 4.85% to $111.48, before settling in for the price of $106.32 at the close. Taking a more long-term approach, BNTX posted a 52-week range of $76.53-$131.49.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 843.27%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -183.36%. This publicly-traded company’s shares outstanding now amounts to $239.74 million, simultaneously with a float of $239.12 million. The organization now has a market capitalization sitting at $26.73 billion. At the time of writing, stock’s 50-day Moving Average stood at $113.08, while the 200-day Moving Average is $95.48.
BioNTech SE ADR (BNTX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. BioNTech SE ADR’s current insider ownership accounts for 0.26%, in contrast to 17.92% institutional ownership.
BioNTech SE ADR (BNTX) Earnings and Revenue Records
BioNTech SE ADR’s EPS decrease for this current 12-month fiscal period is -183.36% and is forecasted to reach -3.27 in the upcoming year.
BioNTech SE ADR (NASDAQ: BNTX) Trading Performance Indicators
Let’s observe the current performance indicators for BioNTech SE ADR (BNTX). It’s Quick Ratio in the last reported quarter now stands at 7.21. The Stock has managed to achieve an average true range (ATR) of 4.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.10. Similarly, its price to free cash flow for trailing twelve months is now 18.08.
In the same vein, BNTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.15, a figure that is expected to reach 0.67 in the next quarter, and analysts are predicting that it will be -3.27 at the market close of one year from today.
Technical Analysis of BioNTech SE ADR (BNTX)
Going through the that latest performance of [BioNTech SE ADR, BNTX]. Its last 5-days volume of 1.02 million indicated improvement to the volume of 0.79 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 49.40% While, its Average True Range was 4.61.
Raw Stochastic average of BioNTech SE ADR (BNTX) in the period of the previous 100 days is set at 63.59%, which indicates a major fall in contrast to 67.47% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 36.27% that was lower than 45.75% volatility it exhibited in the past 100-days period.
